Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
Inventors
Han, Sangdon • Kim, Sun Hee • ZHU, Yunfei
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.
Core Innovation
The patent claims compounds of Formula (I), subseries thereof, and related scaffold families as melanocortin receptor modulators, particularly MC2R antagonists, or pharmaceutically acceptable salts or solvates thereof. Formula (I) defines alternatives for substituents, aromatic groups, linkers, and ring systems, wherein at least one of L and M is —O—. The disclosed compounds include substituted bipyridines containing piperazine or piperidine groups with varied aromatic, heterocyclic, heteroaryl, amine, amide, sulfonamide, sulfanyl, and sulfonyl variants.
The description encompasses stereoisomers, isotopically labeled compounds, prodrugs, active metabolites, and specifically enumerated compounds, reporting hMC2R binding potency where most tested compounds show a Ki below 100 nM. An independent claim recites a specifically listed set of substituted bipyridine and related compounds for reducing adrenocorticotropic hormone secretion and treating conditions such as Cushing's syndrome. Because introductory sections are omitted, the problem being solved is not explicitly described in patent.
Claims Coverage
The provided claim information identifies two independent claims encompassing two inventive features.
Formula (I) compound genus
Independent claim 1 covers a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, defining alternatives for substituents, aromatic groups, linkers, and ring atoms, with the proviso that at least one of L and M is —O—.
Specifically enumerated compounds
A separate independent claim covers a specified list of substituted bipyridine and related compounds containing piperazine or piperidine moieties with varied aromatic, heterocyclic, amine, amide, sulfonamide, sulfanyl, or sulfonyl substituents, or a pharmaceutically acceptable salt or solvate thereof.
The independent claims cover both a broad Formula (I) genus and an extensive list of specifically recited compounds, supported by dependent claims for pharmaceutical compositions, reduction of ACTH secretion, and treatment of specified diseases.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Pharmaceutical compositions comprising a claimed compound, pharmaceutically acceptable salt, or solvate, and at least one pharmaceutically acceptable excipient.
Treatment of Cushing’s syndrome, ectopic Cushing’s syndrome, ectopic ACTH syndrome, or congenital adrenal hyperplasia (CAH) in a mammal by administering a claimed compound, pharmaceutically acceptable salt, or solvate.
Reduction of adrenocorticotropic hormone (ACTH) secretion in a mammal by administering a claimed compound, pharmaceutically acceptable salt, or solvate.
Modulating MC2R, including the use of the compounds as MC2R antagonists.
Interested in licensing this patent?